Published Nov 25, 2022, in the highly respected peer-reviewed journal Phytotherapy Research, results show a statistically significant reduction in the duration of illness and severity scores of the symptoms associated with Covid-19. In addition, statistical significance was seen in the alleviation of symptoms such as taste and smell from Day 5. Most importantly, there was statistical significance in the reduction of Interleukin-6, the key biomarker that is the predictor of immune dysregulation, acute respiratory distress, mortality, and Long-COVID. A further subset analysis showed adjunctive effects with the standard of care with Remdesivir. The full article can be read at Chitre, D., Nadkarni, S., Jagtap, N., Tulle, R., Gitte, A., Rahate, P., Chaskar, S., & Dey, D. (2022). Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2 infections and its impact on inflammatory biomarkers. Phytotherapy Research, 1–10. https://doi.org/10.1002/ptr.7683.
“We are very encouraged by the results of our study,” said the CEO, Deepa Chitre, MD. She further said that Artovid-20® is one of the most scientifically validated products from the science of Ayurveda. Bioved has a proprietary and US-patented method of extraction of natural plants. Rapid testing and full pre-clinical development are conducted at the Company’s subsidiary in Pune, India. “We have US FDA-registered and audited Laboratories in India,” said Dr. Chitre. Artovid-20® has undergone extensive toxicity studies to prove that it is safe. With the recent results of this double-blind placebo-controlled multi-center study, there is potential that this product can be used as an immuno-modulator to help other viral infections, and for Long-COVID.
Bioved is headquartered in San Jose, California with subsidiaries in Pune, India, and Hanoi, Vietnam. “We have a very robust Discovery Platform for safe and effective, natural plant-based nutraceuticals, dietary supplements, and OTC products from the Science of Ayurveda. Our products are marketed in several countries in Asia-Pacific and the US. We desire to make Artovid-20® tablets available to the masses, especially in developing nations who have and are still suffering from the challenges of Covid-19.” As a minority woman-owned business, Dr. Chitre takes pride in the science and quality control that Bioved puts into every product.
More information about the Company and its products can be obtained at www.bioved.com. For distribution and other inquiries please write to [email protected].
SOURCE: Bioved Pharmaceuticals, Inc.
